肺移植、心肺联合移植、肝肾联合肺移植和造血干细胞移植联合肺移植概述。

Overview of Lung Transplantation, Heart-Lung Transplantation, Liver-Lung Transplantation, and Combined Hematopoietic Stem Cell Transplantation and Lung Transplantation.

机构信息

Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic Foundation, A-90, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

Lung Transplant and Heart Lung Transplant Program, Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic Foundation, A-90, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

出版信息

Clin Chest Med. 2017 Dec;38(4):623-640. doi: 10.1016/j.ccm.2017.07.004. Epub 2017 Sep 21.

DOI:10.1016/j.ccm.2017.07.004

PMID:29128014

Abstract

Lung transplantation (LTx) has evolved to represent the therapy of choice for many patients with end-stage lung diseases. Appropriate candidate selection for LTx is an important determinant of a positive outcome from transplantation. Posttransplantation survival has steadily improved, but long-term survival continues to be a challenge with a median survival of 5.8 years. Similarly, combined heart-lung transplantation and simultaneous liver-lung transplantation has been performed successfully in select patients who are not expected to survive either organ transplant alone. Moreover, LTx has been performed in patients who develop end-stage pulmonary complications following hematopoietic stem cell transplantation.

摘要

肺移植（LTx）已经发展成为许多终末期肺部疾病患者的首选治疗方法。LTx 的合适候选者选择是移植后获得积极结果的重要决定因素。移植后的生存率稳步提高，但长期生存率仍然是一个挑战，中位生存率为 5.8 年。同样，在单独进行器官移植预期无法存活的特定患者中，成功地进行了心脏-肺联合移植和同时进行的肝-肺移植。此外，在造血干细胞移植后出现终末期肺部并发症的患者中也进行了 LTx。